Items in cart [1] Questions? Call 888-624-8373

PAPERBACK list:$32.50 Web:$29.25 add to cart Rights & Permissions Free PDF Access Free Resources Sign in to download PDF book and chapters PDF EXECUTIVE SUMMARY Display this book on your site! Related Titles Cancer Biomarkers: The Promises and Challenges of Improving Detection and Treatment Developing Biomarker-Based Tools for Cancer Screening, Diagnosis, and Treatment: The State of the Science, Evaluation, Implementation, and Economics Workshop Summary Other Related Titles Neuroscience Biomarkers and Biosignatures: Converging Technologies, Emerging Partnerships: Workshop Summary (2008) Board on Health Sciences Policy (HSP) Web Search Builder Use this book's key terms to search within this book, across our collection, or across the Web. Skim This Chapter Skim this chapter and use this chapter's key terms to search within this book. Reference Finder Paste in your own text to find books that relate to your topic. Page 87   E-mail  Facebook  Digg  Stumble  Twitter More The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. C Workshop Attendees C. Anthony Altar National Institutes of Health Oscar Alzate Duke University C. Dennis Barton Johns Hopkins University Sally Berry Johnson & Johnson Linda Brady National Institute of Mental Health Sarah Comley International Observers Jeff Cossman The Critical Path Institute Raymond Crowel Mental Health America Mark Day Maryellen de Mars The Critical Path Institute Susan Feldman New Jersey Medical School Jarlath French-Mullen GeneLogic, Inc. Steve Foote National Institute of Mental Health Philip Fung National Institutes of Health Alycia Halladay Autism Speaks Therese Heinonen Critical Markers of Disease Julia Heinrich Wyeth Research Page 87 Front Matter (R1-R12) Summary (1-8) Introduction (9-14) 1 Biomarker and Biosignature Principles (15-26) 2 Potential Tools for Biomarker and Biosignature Development (27-38) 3 Psychiatric and Drug Addiction Disorders (39-54) 4 Neurological and Eye Diseases (55-70) A References (71-80) B Public Workshop on Neuroscience Biomarkers and Biosignatures: Converging Technologies, Emerging Partnerships (81-86) C Workshop Attendees (87-90) D Biographical Sketches of Invited Speakers, Committee Members, and Staff (91-116)

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 87
Neuroscience Biomarkers and Biosignatures: Converging Technologies, Emerging Partnerships, Workshop Summary C Workshop Attendees C. Anthony Altar National Institutes of Health Oscar Alzate Duke University C. Dennis Barton Johns Hopkins University Sally Berry Johnson & Johnson Linda Brady National Institute of Mental Health Sarah Comley International Observers Jeff Cossman The Critical Path Institute Raymond Crowel Mental Health America Mark Day Maryellen de Mars The Critical Path Institute Susan Feldman New Jersey Medical School Jarlath French-Mullen GeneLogic, Inc. Steve Foote National Institute of Mental Health Philip Fung National Institutes of Health Alycia Halladay Autism Speaks Therese Heinonen Critical Markers of Disease Julia Heinrich Wyeth Research

OCR for page 88
Neuroscience Biomarkers and Biosignatures: Converging Technologies, Emerging Partnerships, Workshop Summary Bruce Hermann Epilepsy Foundation Kazunari Hirata Raquel Huerta Rutgers University and University of Medicine and Dentistry of New Jersey Ekopimo Ibia Merck Research Laboratories Carlayne Jackson American Academy of Neurology John Lawson Innogenetics Daniel Lee Biogenidec, Inc. David Lee Foundation for the National Institutes of Health Carole DeSpain Magoffin National Minority Quality Forum Steven Marcus Columbia University Amy McGuire Foundation for the National Institutes of Health Roger Meyer American College of Neuropsychopharmacology Thomas Miller National Institutes of Health Ryan Mitchell Pennslvania State University, College of Medicine Susan Molchan National Institutes of Health Avindra Nath Johns Hopkins University Lisa Neuhold National Institute on Alcohol Abuse and Alcoholism Steven Niemi Patricia O’Looney National Multiple Sclerosis Society Carlos Pardo Johns Hopkins University, School of Medicine Mark Rasenick University of Illinois, College of Medicine Dr J. Tilak Ratnanather Johns Hopkins University

OCR for page 89
Neuroscience Biomarkers and Biosignatures: Converging Technologies, Emerging Partnerships, Workshop Summary Scott Reines Johnson & Johnson Judith Rumsey National Institutes of Health Joshua Schulman Randall Smith University of Pittsburg, School of Pharmacy Jan Teller East Carolina University, Brody School of Medicine Hong Wan Wyeth David Wholley Foundation for the National Institutes of Health Dean Wong American College of Neuropsychopharmacology Jimmy Zhang Johnson & Johnson Yantian Zhang National Institute of Biomedical Imaging and Bioengineering

OCR for page 90
Neuroscience Biomarkers and Biosignatures: Converging Technologies, Emerging Partnerships, Workshop Summary This page intentionally left blank.